Zilbrysq

zilucoplan · UCB Pharma S.A.
AUTHORISED IN THE EU

What Zilbrysq is used for

Zilbrysq is indicated as an add-on to standard therapy for the treatment of generalised myasthenia gravis (gMG) in adult patients who are anti-acetylcholine receptor (AChR) antibody positive.

Approved use, as published by the European Medicines Agency.

Key facts

Brand
Zilbrysq
Active substance
zilucoplan
Disease area
Myasthenia Gravis
Medicine group
Immunosuppressants
ATC code
L04AJ06
Marketing authorisation holder
UCB Pharma S.A.
Authorised in the EU since
2023

Official information

Specialist medicine: started and supervised by a specialist doctor or hospital. This page is a plain-language summary of public official information, not medical advice; follow your doctor and the official product information.

Common questions

What is Zilbrysq used for?

Zilbrysq is indicated as an add-on to standard therapy for the treatment of generalised myasthenia gravis (gMG) in adult patients who are anti-acetylcholine receptor (AChR) antibody positive.

What is the active substance in Zilbrysq?

Zilbrysq contains zilucoplan.

Who makes Zilbrysq?

The EU marketing authorisation holder is UCB Pharma S.A..

Source: European Medicines Agency medicines data (ema.europa.eu), reproduced with acknowledgement of the source. Page made 5 November 2026 by Satya Babu.

← All specialty medicines, EU

For information only, not medical advice. This page is a plain-language summary written from standard prescribing information and the public guides linked below. Brands sometimes change their formula, so always check the composition printed on the pack. Doses here are typical adult doses; yours may differ. Do not start, stop or change a medicine without your doctor or pharmacist, and keep all medicines away from children. In an emergency, call 112 (India) or your local emergency number.